Phase 4Completed
CARDS Is Designed To Show If Lowering Cholesterol With Atorvastatin In Type 2 Diabetics Without CV Disease Reduces The Risk Of CV Events
A Double Blind Placebo Controlled Study of Atorvastatin as Prevention of CHD in High Risk Patients With Non-Insulin Dependent Diabetes Mellitus (Collaborative Atorvastatin Study - CARDS)
- Sponsor
- Pfizer (Industry)
- Enrollment
- 2,800 planned
- Conditions
- Major Coronary Event; Cerebrovascular Accident; Coronary Artery Bypass Graft; Angina, Unstable; Revascularization
- Interventions
- Atorvastatin
- Ages
- adults, older adults
- Registry
- NCT00327418
Full record on ClinicalTrials.gov
From the registry
A study to assess the efficacy of once daily atorvastatin 10 mg versus placebo on cardiovascular endpoints in patients with non-insulin-dependent diabetes mellitus (NIDDM) who have a history of either hypertension, retinopathy, microalbuminuria, macroalbuminuria, or who currently smoke, but who do not have established corornary heart disease or other macrovascular disease.
Primary outcomes
- Time from randomization to the occurrence of a primary clinical endpoint
- i.e. major coronary event or CABG or other coronary revascularization procedure
- or unstable angina or resuscitated cardiac arrest or stroke.
History
Last registry update
Registered
Study completion
Started